newsfilter
← Latest News
Business Wire·

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

Product Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial Reported additional preclinical data for EB-003